Professional Documents
Culture Documents
2 Running Title: A short running title of less than 6 words should be provided.
to conception and design, acquisition of data, or analysis and interpretation of data; (2)
drafting the article or revising it critically for important intellectual content; and (3) final
4 Received: Fill out by S-editor; Revised: Fill out by S-editor; Accepted: Fill out by S-
5 Abstract: There are unstructured abstracts (no more than 256 words) and
structured abstracts (no more than 480). The specific requirements for structured
each manuscript. Abstracts for original contributions should be structured into the
following sections. AIM (no more than 20 words): Only the purpose should be
included. Please write the aim as the form of “To investigate/study/…; MATERIALS
AND METHODS(no more than 140 words); RESULTS (no more than 294 words): You
should present P values where appropriate and must provide relevant data to illustrate
how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67, P < 0.001; CONCLUSION (no
6 Keywords: Please list 5-10 key words for each manuscript, selected mainly from Index
Medicus, which reflect the content of the study. Each key word is separated by a
semicolon.
the text). Avoid repetitions of data in the text, tables, and illustration. Explain tersely the
symbols, letters, or number used. Indicate the number and character of observations and
1
subjects. Identify statistical significance by superscripts in front of the probabilities (P),
8.1 Figures: You should provide decomposable figures with a size of 5 : 7 (height :
width) in general. The curves or straight lines should be clear. Freehand or typewritten
lettering is unacceptable. Units can not be omitted. Combine related curves in a single
figure when possible. A composite of curves will save space and convey more
multiple curves.
8.2.1 The photographs supplied should be no smaller than 85 mm in height and 126 mm
in width, and at a resolution of 300 dpi as TIFF format. The colour photos should be
saved in TIFF format at a resolution of 300 dpi; each photo in a separate file, and no
8.2.2 Images submitted should be those which uniquely display the data. Figures are not
limited, but must be thoroughly justified. For figures that have multiple panels, the labels
should be set in uppercase Helvetica or Arial letters and should not contain periods or
parentheses. Please be sure to embed all fonts. Micrographs should be provided with a
Photoshop or Illustrator files (in tiff, psd, eps, ai, pdf, or JPEG formats) at 300 dpi
professional in-house illustrator will work with authors to ensure the highest quality and
clarity of published figures. Please provide only one legend for each photo or figure that
contains all the pertinent information. Figures or photos should be grouped according to
their themes. For example, Figure 1 Pathological changes of atrophic gastritis tissue
symbols, arrows, numbers, or letters in the illustrations. Identify the method of staining
and magnification of the photomicrographs (eg, HE stain, ×900). For those including
methodology, the legend should be no more than 100 words (no more than 500 words in
total). For those not including methodology, the legend should be no more than 300
words (no more than 800 words in total). Letters in photos or figures should be
2
lowercased while the first one be capitalized. An interval should be inserted between
numbers and units. Photos or figures that are obtained at different time or places must
not be grouped into one, unless those photos or figures are arranged in a time order.
There are intervals between photos or figures of the same group. Photographs or figures
8.2.3 Authors should list the names of tools they use to obtain and edit the image file.
Images must be edited equally and contrast must be reasonable. Editing that is far
between experiment data and control data, or over-emphasize a certain part of the
photos by ignoring some other parts. (A) Electrophoresis and blotting images: must
include negative, positive controls and molecular Marker; provide the reference of the
identified antibodies; explain the specificity and active spectrum of the agents not
identified; band should be clear; important bands must not be deleted; leave six-band
space around the blotting bands; we suggest not use high-contrast blotting, for over-
display may conceal the other bands. Authors should try to exhibit the bands on the gray
background. Black frame may be used if the background is weak. (B) Microscopic or
endoscopic images: cells from different field must not be put in the same field; images
independent page, with a bold title no more than a row long. Tables should be put at the
9 References: Pleased provide PubMed citation numbers to the reference list, e.g. PMID
11 Abstract Contents
3
11.3 UNSTRUCTURED ABSTRACT FORMAT FOR OBSERVER 8
4
Author contributions: Parfieniuk A was responsible for the review of the
literature and initial preparation of the paper, Flisiak R prepared final version
of the manuscript.
Cannabinoids are a group of compounds acting primarily via CB1 and CB2
receptors. The expression of cannabinoid receptors in normal liver is low or
absent. However, many reports have proven up-regulation of the expression
of CB1 and CB2 receptors in hepatic myofibroblasts and vascular endothelial
cells, as well as increased concentration of endocannabinoids in liver in the
course of chronic progressive liver diseases. It has been shown that CB1
5
receptor signalling exerts profibrogenic and proinflammatory effects in liver
tissue, primarily due to the stimulation of hepatic stellate cells, whereas the
activation of CB2 receptors inhibits or even reverses liver fibrogenesis.
Similarly, CB1 receptor stimulation contributes to progression of liver
steatosis. In end-stage liver disease, the endocannabinoid system has been
shown to contribute to hepatic encephalopathy and vascular effects, such as
portal hypertension, splanchnic vasodilatation, relative peripheral
hypotension and probably cirrhotic cardiomyopathy. So far, available evidence
is based on cellular cultures or animal models. Clinical data on the effects of
cannabinoids in chronic liver diseases are limited. However, recent studies
have shown the contribution of cannabis smoking to the progression of liver
fibrosis and steatosis. Moreover, controlling CB1 or CB2 signalling appears to
be an attractive target in managing liver diseases.
Peer reviewer:
HIGHLIGHT
6
Effects of ghrelin on interdigestive contractions of
Hiroshi Taniguchi, Hajime Ariga, Jun Zheng, Kirk Ludwig, Toku Takahashi
Key words: Phase Ⅲ-like contractions; Strain gage transducers; Motility index
8
11.3 UNSTRUCTURED ABSTRACT FORMAT FOR OBSERVER
syndrome
9
Abstract (256 words)
Peer reviewer:
10
J Gastroenterol 2008; 14(42): 6442-6443
Available from: URL: http://www.wjgnet.com/1007-9327/14/6442.asp
DOI: http://dx.doi.org/10.3748/wjg.14.6442
11
Telephone: +01-404-7276454 Fax: +01-404-727-5767
Received: May 14, 2008 Revised: July 28, 2008
Accepted: August 3, 2008
Published online: October 28, 2008
12
© 2008 The WJG Press. All rights reserved.
Peer reviewer:
ARTICLES
Author controbutions: The format of this section should be like this: Author
contributions: Zhou XL and Chen SW contributed equally to this work; Zhou
XL, Chen SW, Liao GD, Shen ZJ, Zhang ZL, Sun L, Yu YJ, Hu QL and Jin XD
designed research; Zhou XL, Chen SW, Liao GDand Yu YJ performed research;
Zhou XL and Chen SW contributed new reagents/analytic tools; Zhang ZL, Hu
QL and Jin XD analyzed data; and Zhou XL, Chen SW,and Jin XD wrote the
paper.
Supported by The National Natural Science Foundation of China, No.
50173023
14
Accepted: Published online:
AIM (no more than 20 words): To comparatively study the preventive effect of
gelatinizedly-modified chitosan film on peritoneal adhesions induced by four
different factors in rats.
15
operation group (group A), wound-induced adhesion group (group B), purified
talc-induced adhesion group (group C), vascular ligation-induced adhesion
group (group D), and infection-induced adhesion group (group E),
respectively. In each group, the rats were treated with different adhesion-
inducing methods at the cecum of vermiform processes and then were
divided into control and experimental subgroups. Serous membrane surface
of vermiform processes were covered with the films in the experimental
subgroups, and no films were used in the control subgroups. After 2 and 4 wk
of treatments, the abdominal cavities were reopened and the adhesive
severity was graded blindly according to Bhatia’s method. The cecum of
vermiform processes were resected for hydroxyproline (OHP) measurement
and pathological examination.
RESULTS(no more than 294 words. You should present P value where necessary and
must provide relevant data to illustrate how it is obtained, e.g. 2 wk: 0.199 ± 0.026 vs
0.285 ± 0.041 μg/mg pr, P < 0.001): Adhesion severity and OHP level: After 2 and
16
vermiform processes. In group E, the main pathological changes were acute
and chronic suppurative inflammatory reactions. These changes were lighter
in the experimental subgroups than those in the control subgroups in the
three groups. In group C, the main changes were foreign body giant cell and
granuloma reactions and fibroplasias in different degrees, with no apparent
differences between the experimental and control subgroups.
Peer reviewer:
Zhou XL, Chen SW, Liao GD, Shen ZJ, Zhang ZL, Sun L, Yu YJ, Hu QL, Jin XD.
Preventive effect of gelatinizedly-modified chitosan film on peritoneal
adhesion of different types. World J Gastroenterol 2007; 13(8): 1262-1267
REPORT
17
Acute ulcerative jejunal diverticulitis: Case report of an
uncommon entity
18
Published online: October 28, 2008
Peer reviewer:
19
Staszewicz W, Christodoulou M, Proietti S, Demartines N. Acute ulcerative
jejunal diverticulitis: Case report of an uncommon entity. World J
Gastroenterol 2008; 14(40): 6265-6267
Available from: URL: http://www.wjgnet.com/1007-9327/14/6265.asp
DOI: http://dx.doi.org/10.3748/wjg.14.6265
THE EDITOR
Paul A Smith
Telephone: +1-61-9240420
Received: April 26, 2008 Revised: July 7, 2008
Accepted: July 14, 2008
20
Published online: July 21, 2008
Peer reviewer:
Smith PA. Nutritional therapy for active Crohn's disease. World J Gastroenterol
2008; 14(27): 4420-4423
Available from: URL: http://www.wjgnet.com/1007-9327/14/4420.asp
DOI: http://dx.doi.org/10.3748/wjg.14.4420
21
22